Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

1.

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC.

Br J Cancer. 2010 Sep 28;103(7):993-1000. doi: 10.1038/sj.bjc.6605852. Epub 2010 Aug 17.

PMID:
20717111
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.

Bello CL, Garrett M, Sherman L, Smeraglia J, Ryan B, Toh M.

Cancer Chemother Pharmacol. 2010 Sep;66(4):699-707. doi: 10.1007/s00280-009-1213-4. Epub 2010 Jan 5.

PMID:
20049443
[PubMed - indexed for MEDLINE]
3.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.

Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5. Review.

PMID:
19967539
[PubMed - indexed for MEDLINE]
4.

Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.

Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL.

J Clin Pharmacol. 2010 Apr;50(4):472-81. doi: 10.1177/0091270009347868. Epub 2009 Sep 24.

PMID:
19779038
[PubMed - indexed for MEDLINE]
5.

An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.

Giannopoulou E, Dimitropoulos K, Argyriou AA, Koutras AK, Dimitrakopoulos F, Kalofonos HP.

Invest New Drugs. 2010 Oct;28(5):554-60. doi: 10.1007/s10637-009-9290-0. Epub 2009 Jul 15.

PMID:
19603143
[PubMed - indexed for MEDLINE]
6.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.

J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

PMID:
19487381
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S.

Ann Oncol. 2009 Sep;20(9):1535-42. doi: 10.1093/annonc/mdp025. Epub 2009 May 27.

PMID:
19474115
[PubMed - indexed for MEDLINE]
Free Article
8.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK.

J Clin Oncol. 2009 Jun 20;27(18):3027-35. doi: 10.1200/JCO.2008.20.9908. Epub 2009 May 26.

PMID:
19470923
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK.

J Clin Oncol. 2009 Jul 1;27(19):3133-40. doi: 10.1200/JCO.2008.20.4495. Epub 2009 May 18.

PMID:
19451436
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML.

J Clin Oncol. 2009 Jul 1;27(19):3154-60. doi: 10.1200/JCO.2008.20.9890. Epub 2009 May 18.

PMID:
19451429
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY.

J Clin Oncol. 2009 Jul 1;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223. Epub 2009 May 18.

PMID:
19451427
[PubMed - indexed for MEDLINE]
12.

In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.

Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S.

Neoplasia. 2009 May;11(5):426-35.

PMID:
19412427
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD.

Pediatr Blood Cancer. 2009 Jul;52(7):767-71. doi: 10.1002/pbc.21909.

PMID:
19326424
[PubMed - indexed for MEDLINE]
14.

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.

Houk BE, Bello CL, Kang D, Amantea M.

Clin Cancer Res. 2009 Apr 1;15(7):2497-506. doi: 10.1158/1078-0432.CCR-08-1893. Epub 2009 Mar 3.

PMID:
19258444
[PubMed - indexed for MEDLINE]
Free Article
15.

Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.

Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VW, Broxterman HJ.

Angiogenesis. 2009;12(1):69-79. doi: 10.1007/s10456-009-9133-9. Epub 2009 Feb 11.

PMID:
19212818
[PubMed - indexed for MEDLINE]
16.

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H.

J Clin Oncol. 2008 Nov 10;26(32):5204-12. doi: 10.1200/JCO.2007.15.6331. Epub 2008 Oct 6.

PMID:
18838713
[PubMed - indexed for MEDLINE]
17.

Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.

Hasinoff BB, Patel D, O'Hara KA.

Mol Pharmacol. 2008 Dec;74(6):1722-8. doi: 10.1124/mol.108.050104. Epub 2008 Sep 24.

PMID:
18815214
[PubMed - indexed for MEDLINE]
Free Article
18.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.

J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.

PMID:
18669461
[PubMed - indexed for MEDLINE]
19.

Molecular characterization of pediatric gastrointestinal stromal tumors.

Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2008 May 15;14(10):3204-15. doi: 10.1158/1078-0432.CCR-07-1984.

PMID:
18483389
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

Telli ML, Witteles RM, Fisher GA, Srinivas S.

Ann Oncol. 2008 Sep;19(9):1613-8. doi: 10.1093/annonc/mdn168. Epub 2008 Apr 23.

PMID:
18436521
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk